- TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon
University to create an artificial intelligence solution to
optimize the donor screening and matching process
- The software could have additional applications across cell
therapy for donor/patient matching
EDINBURGH, Scotland, Oct. 3, 2024
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the
"Company") (NASDAQ: TCBP), a clinical-stage biotechnology company
developing platform allogeneic gamma-delta T cell therapies for
cancer and other indications, today announced it has entered into a
sponsored research agreement with Carnegie
Mellon University to explore the potential use of artificial
intelligence to optimize the patient screening process.
The Company will partner with Dr. Wei
Wu, a faculty member in the Ray and Stephanie Lane
Computational Biology Department within the School of Computer
Science at the renowned university, and her lab to leverage AI to
build a solution that enhances the donor selection process and
matching process. Dr. Wu's research focuses on understanding
complex human diseases through integrative approaches, combining
biology, computational and statistical learning, bioinformatics,
and genomics. The applications for advanced and accurate donor
screening and potential donor/patient matching extend from
increased manufacturing yields, better production processes, and
enhanced patient outcomes among many other benefits. The amount of
variability between donors, similar patients, and the volume of
donors and patients across diseases represents a "big data problem"
which is ideal for applying Artificial Intelligence for a better
understanding and potential solution.
"TC BioPharm is pleased to partner with Carnegie Mellon University as we continue to
research cutting-edge solutions for the advancement of the cell
therapy industry," stated Bryan
Kobel, CEO of TC BioPharm. "Dr. Wu and her laboratory
are helping us tackle another 'big problem' with this endeavor,
which has the potential to revolutionize both the donor selection
and matching processes. An issue the cell therapy industry faces as
a whole is donor variability as well as how to more accurately
predict outcomes and responses between donors and patients. Finding
a solution for how to select the best donors for allogeneic cell
therapies to generate the best product, and also how to match the
best cell therapy and donor to the best patient beyond the current
HLA matching process, represents a massive opportunity from a
market perspective and also would have far-reaching applications
for CDMOs and other industry players. Bringing in Dr. Wu for this
'big data problem' is the first step. She and Carnegie Mellon University are at the forefront of
the AI industry, and it's an honor to work with her and the
esteemed university. Artificial intelligence has the potential to
deliver significant breakthroughs in the worlds of medicine and
science, and we are excited to embrace its possibilities."
Dr. Wei Wu added, "I am excited
about this partnership with TC BioPharm. With the integration of
cutting-edge AI technology into cell therapy research,
this collaboration holds a lot of promise for advancing the field
and addressing key challenges such as donor variability. Optimizing
donor selection and donor/patient pairing with AI could lead to
solutions to some of the most pressing challenges in cell therapy,
with the potential to improve patient outcomes. I'm excited that
our team will be part of this effort. Given the significant
potential of AI to transform industries, this partnership could
open new doors for precision medicine and personalized cell
therapies."
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 8-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid
leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
View original
content:https://www.prnewswire.com/news-releases/tcbp-announces-artificial-intelligence-initiative-with-partner-carnegie-mellon-university-for-donor-screening-302265858.html
SOURCE TC BioPharm
